Pharmafile Logo

Infographic: RA Perceptions

HCPs predict the future of the biologics market

Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.

Download our RA Perceptions: Predicting the future of the European market infographic now »

RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.

Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.

Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.

Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.

The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?

In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Webcast: Evolving Patient Journeys – How to generate deeper insights in a changing healthcare landscape

Watch part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years.

Infographic: Living with: The journey from the patient’s perspective

View our re-vamped interactive infographic to unlock key insights from various Living With reports

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO